Journal of Psychosomatic Research
Volume 63, Issue 6 , Pages 625-632 , December 2007

Tailored psychotherapy for patients with functional neurological symptoms: A pilot study

  • Markus Reuber

      Affiliations

    • Academic Unit of Neurology, Division of Genomic Medicine, University of Sheffield, Royal Hallamshire Hospital, Sheffield, United Kingdom
    • Corresponding Author InformationCorresponding author. Academic Unit of Neurology, Division of Genomic Medicine, University of Sheffield, Royal Hallamshire Hospital, Glossop Road, S10 2JF Sheffield, United Kingdom. Tel.: +44 0114 2268763; fax: +44 0114 2713684.
    • ,
  • Christine Burness

      Affiliations

    • Department of Neurology, Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, United Kingdom
    • ,
  • Stephanie Howlett

      Affiliations

    • Department of Neurology, Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, United Kingdom
    • ,
  • John Brazier

      Affiliations

    • School of Health and Related Research, Regent Court, Sheffield, United Kingdom
    • ,
  • Richard Grünewald

      Affiliations

    • Department of Neurology, Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, United Kingdom

Received 2 February 2007 ,Revised 14 May 2007 ,Accepted 19 June 2007.

References 

  1. Carson AJ, Ringbauer B, Stone J, McKenzie L, Warlow C. Do medically unexplained symptoms matter? A prospective cohort study of 300 new referrals to neurology outpatients. J Neurol Neurosurg Psychiatry. 2000;68:207–210
  2. Carson AJ, Ringbauer B, MacKenzie L, Warlow C, Sharpe M. Neurological disease, emotional disorder, and disability: they are related. A study of 300 consecutive new referrals to a neurology outpatient department. J Neurol Neurosurg Psychiatry. 2000;68:202–206
  3. World Health Organization . The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: WHO; 1992;
  4. American Psychiatric Association . Diagnostic and statistical manual of mental disorders. Washington, DC: APA; 1994;
  5. Reuber M, Mitchell AJ, Howlett S, Crimlisk CH, Grünewald R. Functional symptoms in neurology: questions and answers. J Neurol Neurosurg Psychiatry. 2005;76:307–314
  6. Fink P, Sorensen L, Engberg M, Holm M, Munk-Jorgensen P. Somatization in primary care—prevalence, health care utilization and general practitioner recognition. Psychosomatics. 1999;40:331–338
  7. Kroenke K, Spitzer RL, Williams JB, Linzer M, Hahn SR, deGruy FV, et al. Physical symptoms in primary care. Predictors of psychiatric disorders and functional impairment. Arch Fam Med. 1994;3:774–779
  8. Stone J. Functional weakness. PhD Thesis, University of Edinburgh 2006.
  9. Binzer M, Stone J, Sharpe M. Recent onset pseudoseizures—clues to aetiology. Seizure. 2004;13:146–155
  10. Reuber M, Howlett S, Khan A, Grünewald R. Nonepileptic seizures and other functional neurological symptoms: predisposing, precipitating and perpetuating factors. Psychosomatics 2007;48:230­8.
  11. Carson AJ, Best S, Warlow C, Sharpe M. Suicidal ideation among outpatients at general neurology clinics: an outpatient study. Br Med J. 2000;320:1311–1312
  12. Reid S, Wessely S, Crayford T, Hotopf M. Frequent attenders with medically unexplained symptoms: service use and costs in secondary care. Br J Psychiatry. 2002;180:248–253
  13. LaFrance WC, Barry JJ. Update on treatments of psychological nonepileptic seizures. Epilepsy Behav. 2005;7:364–374
  14. Reuber M, Howlett S, Kemp S. Psychologic treatment for patients with psychogenic nonepileptic seizures. Exp Op Neurotherapeut. 2005;5:737–752
  15. Sharpe M, Peveler R, Mayou R. The psychological treatment of patients with functional somatic symptoms: a practical guide. J Psychosom Res. 1992;36:515–529
  16. Looper KJ, Kirmayer LJ. Behavioral medicine approaches to somatoform disorders. J Consult Clin Psychol. 2002;70:810–827
  17. Brown RJ. Medically unexplained symptoms. In:  Tarrier N editors. Case formulation in cognitive behaviour therapy. London: Routledge; 2006;p. 263–292
  18. Parry G. NHS psychotherapy services in England—review of strategic policy. London: Crown Copyright; 1996;
  19. Howlett S, Grünewald R, Khan A, Reuber M. Engagement in psychological treatment for functional neurological symptoms—barriers and solutions. Psychotherapy Theory, Research, Practice, Training [In press].
  20. Kishore GS, Blair A, Scholes K, Reuber M. Outcome of a referral for psychotherapy of patients with functional neurological symptoms or psychiatric disorders presenting to a neurologist. J Neurol Neurosurg Psychiatry. 2005;76:1321
  21. Hobson RF. Forms of feeling. London: Tavistock; 1985;
  22. Shapiro DA, Firth J. Prescriptive v. exploratory psychotherapy. Outcomes of the Sheffield Psychotherapy Project. Br J Psychiatry. 1987;151:790–799
  23. Creed F, Fernandes L, Guthrie E, Palmer S, Ratcliffe J, Read N, et al. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology. 2003;124:303–317
  24. Guthrie E, Creed F, Dawson D, Tomeson B. A controlled trial of psychological treatment for irritable bowel syndrome. Gastroenterology. 1991;100:450–457
  25. Cahill J, Barkham M, Stiles WB, Twigg E, Hardy GE, Rees A, et al. Convergent validity of the CORE measures with measures of depression for clients in cognitive therapy for depression. J Couns Psychol. 2006;53:253–259
  26. Leach C, Lucock M, Barkham M, Stiles WB, Noble R, Iveson S. Transforming between Beck Depression Inventory and CORE-OM scores in routine clinical practice. Br J Clin Psychol. 2006;45:153–166
  27. Ware JE, Kosinski M, Gandek B. SF36 (R) Health Survey manual and interpretation guide. Lincoln (RI): Qualimetric Incorporated; 2000;
  28. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21:271–292
  29. Spitzer RL, Williams JB, Kroenke K, Linzer M, deGruy FV, Hahn SR, et al. Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 Study. J Am Med Assoc. 1994;272:1749–1756
  30. Kroenke K, Spitzer RL, Williams JBW. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med. 2002;64:258–266
  31. Baker GA, Brooks JL, Goodfellow L, Bodde N, Aldenkamp A. Treatments for non-epileptic attack disorder. Cochrane Database Syst Rev. 2007;24:CD006370
  32. Kroenke K, Swindle R. Cognitive–behavioral therapy for somatization and symptom syndromes: a critical review of controlled clinical trials. Psychother Psychosom. 2000;69:205–215
  33. Roth A, Fonagy P. What works for whom? A critical review of psychotherapy research. New York: The Guilford Press; 2005;
  34. Barsky AJ, Ahern D. Cognitive behavior therapy for hypochondriasis. J Am Med Assoc. 2004;291:1464–1470
  35. National Institute of Clinical Excellence . Post-traumatic stress disorder (PTSD)—the management of PTSD in adults and children in primary and secondary care. London: National Institute of Clinical Excellence; 2005;
  36. Wildgoose A, Clarke S, Waller G. Treatment of personality fragmentation and dissociation in borderline personality disorder: a pilot study of the impact of cognitive analytical therapy. Br J Med Psychol. 2001;74:47–55
  37. McMain S, Korman LM, Dirneff L. Dialectical behavior therapy and the treatment of emotion dysregulation. J Clin Psychol. 2001;57:183–196
  38. O'Malley PG, Jackson JL, Santoro J, Tomkins G, Balden E, Kroenke K. Antidepressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract. 1999;48:980–990
  39. Stone J, Sharpe M, Rothwell PM, Warlow CP. The 12-year prognosis of unilateral functional weakness and sensory disturbance. J Neurol Neurosurg Psychiatry. 2003;74:591–596
  40. Reuber M, Pukrop R, Bauer J, Helmstaedter C, Tessendorf N, Elger CE. Outcome in psychogenic nonepileptic seizures: 1 to 10-year follow-up in 164 patients. Ann Neurol. 2003;53:305–311
  41. Crimlisk HL, Bhatia K, Cope H, David A, Marsden CD, Ron MA. Slater revisited: 6 year follow up study of patients with medically unexplained motor symptoms. Br Med J. 1998;316:582–586
  42. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. Br Med J. 2004;329:224–227
  43. Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, et al. Clinical effectiveness, tolerability and cost-effectiveness of newer antiepileptic drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess. 2005;9:1–157
  44. Chilcott J, McCabe C, Tappenden P, O'Hagan A, Cooper NJ, Abrams K, et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: Evaluating disease modifying treatments in multiple sclerosis. Br Med J. 2003;326:522
  45. Juarez-Garcia A, Stokes T, Shaw B, Camosso-Stefinovic J, Baker R. The costs of epilepsy misdiagnosis in England and Wales. Seizure. 2006;15:598–605
  46. Smith GR, Rost K, Kashner TM. A trial of the effect of a standardized psychiatric consultation on health outcomes and costs in somatizing patients. Arch Gen Psychiatry. 1995;52:238–243
  47. Bleichhardt G, Timmer B, Rief W. Cognitive–behavioural therapy for patients with multiple somatoform symptoms: a randomized controlled trial in tertiary care. J Psychosom Res. 2004;56:449–454
  48. Pinson L, Gray GE. Psychopharmacology: number needed to treat: an underused measure of treatment effect. Psychiatr Serv 2003;54:145–6, 154.

☆ This study was undertaken at the Sheffield Teaching Hospitals NHS Foundation Trust Department of Neurology.

PII: S0022-3999(07)00255-3

doi: 10.1016/j.jpsychores.2007.06.013

Journal of Psychosomatic Research
Volume 63, Issue 6 , Pages 625-632 , December 2007

Article Tools

* Image Usage & Resolution